Showing 5031-5040 of 7169 results for "".
- Anti-Interleukin-23 Monoclonal Antibody Guselkumab: Significant Efficacy In Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140324-anti-interleukin-23_monoclonal_antibody_guselkumab_significant_efficacy_in_moderate_to_severe_plaque_psoriasis/2459298/New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal a
- Phase I Trial of Nivolumab Shows Long-Term Efficacy Against Melanomahttps://practicaldermatology.com/news/20140313-phase_i_trial_of_nivolumab_shows_long-term_efficacy_against_melanoma/2459318/A recent study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions, published online in the Journal of Clinical Oncology, provides the longest-term look so far at how melanom
- Novartis Announces EU Approval of Xolair for Chronic Spontaneous Urticaria Patients Unresponsive to Antihistamineshttps://practicaldermatology.com/news/20140307-novartis_announces_eu_approval_of_xolair_for_chronic_spontaneous_urticaria_patients_unresponsive_to_antihistamines/2459322/
- Michelson Diagnostics Launches Enhanced Software for VivoSight OCT Scannerhttps://practicaldermatology.com/news/20140219-michelson_diagnostics_launches_enhanced_software_for_vivosight_oct_scanner/2459339/Michelson Diagnostics recently launched its upgraded VivoSight Optical Coherence Tomography (OCT) scanner with a new software technology that provides additional f
- Cosmetic Surgery Forum Offers Early-Bird Registrationhttps://practicaldermatology.com/news/20140204-cosmetic_surgery_forum_offers_early-bird_registration/2459349/
- Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn to Treat Mild to Moderate Acnehttps://practicaldermatology.com/news/20140204-oculus_innovative_sciences_receives_european_ce_mark_for_use_of_microcyn_to_treat_mild_to_moderate_acne/2459350/
- Study Finds Prevalence of Indoor Tanning Common in US, Europe, and Australiahttps://practicaldermatology.com/news/20140130-study_finds_prevalence_of_indoor_tanning_common_in_us_europe_and_australia/2459355/
- Merz Dermatology Announces Enhanced Naftin Co-Payment Savings Programhttps://practicaldermatology.com/news/20140117-merz_dermatology_announces_enhanced_naftin_co-payment_savings_program/2459370/
- Scioderm Initiates Phase IIB Study of SD-101 to Treat Epidermolysis Bullosahttps://practicaldermatology.com/news/20140107-scioderm_initiates_phase_iib_study_of_sd-101_to_treat_epidermolysis_bullosa/2459377/
- KYTHERA Biopharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conferencehttps://practicaldermatology.com/news/20140107-kythera_biopharmaceuticals_to_present_at_32nd_annual_jp_morgan_healthcare_conference/2459378/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.